International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

All What You Need To Know About the Lymphatic Filariasis

Islam Khalid Kamal, Atyaf Talal Mahmood, Alaa younis Al-Hamadany

Department of Clinical Laboratory Sciences, College of Pharmacy, Iraq; Department of Anesthesia Techniques, Medical Techniques Institute, Northern, Iraq

Article Information

Volume / Issue6 / 3 (July-September 2025)
Pages42-61
AccessOpen Access

Publication Timeline

  • Received24 May 2025
  • Accepted23 June 2025
  • Published

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

Parasitic diseases are rare in the world but have gained importance with the rise in refugees, leading to millions affected individuals in the region. Symptoms from diseases like lymphoedema may appear years later in migrants and tourists. Specific parasites like W. bancrofti and T. b. rhodesiense are found in Uganda, with cases clustering in certain areas. In a study of 1000 people, around 15 showed significant symptoms of lymphatic filariasis (LF), often overlooked in Latin America. LF mainly occurs in low Andean areas and is transmitted by mosquitoes, with chronic conditions like elephantiasis being serious health concerns. Treatment for LF includes surgery, especially for hydrocele, which can improve health outcomes. Acute symptoms arise from dying adult worms, while chronic symptoms develop over years, with some patients seeking traditional remedies. Diagnosis can be done through blood tests and imaging. The Global Programme to Eliminate Lymphatic Filariasis (GPELF) aims to eradicate LF through mass treatment and research on effective antifilarial drugs. Despite successes in some countries, LF continues to pose public health challenges, affecting millions with economic impacts. Ongoing research into vaccines and treatments is crucial for better management and control of LF.

Keywords

Lymphatic FilariasisParasitic DiseasesWuchereria bancrofti

References

  1. Gabrielli AF, Garba Djirmay A. Schistosomiasis in Europe. Curr Trop Med Rep. 2023;10:79 -87. doi:10.1007/s40475-023-00286-9 [Google Scholar][Crossref]
  2. Mwesigye V, Musinguzi B, Okongo B, Mucunguzi W, Kakaire M, Migisha R. Sero-antigen prevalence of lymphatic filariasis and risk factors of podoconiosis in Busiriba sub-county, Kamwenge district, Southwestern Uganda, August–September 2018. BMC Res Notes. International Journal of Medical and All Body Health Research www.allmedicaljournal.com 2024;17(1):141. [Google Scholar][Crossref]
  3. Bagonza A, Gibson L, Kabiri L, Bezalel C, Narahari SR, Franks PJ, et al. Exploring barriers to accessing treatment for lymphatic filariasis through a socio-ecological lens in Buvuma and Napak districts, Uganda. PLoS Negl Trop Dis. 2025;19(1):e0012747. [Google Scholar][Crossref]
  4. Dietrich CF, Chaubal N, Hoerauf A, Kling K, Piontek MS, Steffgen L, et al. Review of dancing parasites in lymphatic filariasis. Ultrasound Int Open. 2019;5(2):E65-74. doi:10.1055/a-0918-3678 [Google Scholar][Crossref]
  5. Cassidy T, Worrell CM, Little K, Prakash A, Patra I, Rout J, et al. Experiences of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India: an analysis of focus group discussions with patients, families, community members and program volunteers. PLoS Negl Trop Dis. 2016;10(2):e0004424. doi:10.1371/journal.pntd.0004424 [Google Scholar][Crossref]
  6. Medeiros ZM, Vieira AV, Xavier AT, Bezerra GS, Lopes MDFC, Bonfim CV, et al. Lymphatic filariasis: A systematic review on morbidity and its repercussions in countries in the Americas. Int J Environ Res Public Health. 2021;19(1):316. [Google Scholar][Crossref]
  7. Ramesh A, Oliveira P, Cameron M, Castanha PM, Walker T, Lenhart A, et al. Postintervention immunological and entomological survey of lymphatic filariasis in the city of Olinda, Brazil, 2015–2016. Am J Trop Med Hyg. 2024;110(3):470. [Google Scholar][Crossref]
  8. Izquierdo-Condoy JS, Naranjo-Lara P, Vásconez-Gonzalez J, Fernandez-Naranjo R, Placencia-André R, Davila MG, et al. A nationwide epidemiological and geodemographic analysis of lymphatic filariasis in Ecuador: a neglected and often forgotten disease in Ecuador. Front Public Health. 2023;11:1270015. [Google Scholar][Crossref]
  9. Ortiz-Prado E, Simbaña-Rivera K, Barreno LG, Diaz AM, Barreto A, Moyano C, et al. Epidemiological, socio-demographic and clinical features of the early phase of the COVID-19 epidemic in Ecuador. PLoS Negl Trop Dis. 2021;15(1):e0008958. [Google Scholar][Crossref]
  10. Ngowi EE, Wang YZ, Qian L, Helmy YASH, Anyomi B, Li T, et al. The application of nanotechnology for the diagnosis and treatment of brain diseases and disorders. Front Bioeng Biotechnol. 2021;9:629832. [Google Scholar][Crossref]
  11. ElShewy K. Blood and lymphatic parasites. In: Medical Parasitology. Cham: Springer; 2024. p. 165-89. doi:10.1007/978-3-031-64736-9_12 [Google Scholar][Crossref]
  12. Heylen DJ, Kumsa B, Kimbita E, Frank MN, Muhanguzi D, Jongejan F, et al. Tick-borne pathogens and body condition of cattle in smallholder rural livestock production systems in East and West Africa. Parasit Vectors. 2023;16(1):117. [Google Scholar][Crossref]
  13. World Health Organization. Ending the neglect to attain the sustainable development goals: a rationale for continued investment in tackling neglected tropical diseases 2021–2030. Geneva: WHO; 2022. [Google Scholar][Crossref]
  14. Abdoli A, Olfatifar M, Eslahi AV, Moghadamizad Z, Samimi R, Habibi MA, et al. A systematic review and meta-analysis of protozoan parasite infections among patients with mental health disorders: an overlooked phenomenon. Gut Pathog. 2024;16(1):7. doi:10.1186/s13099-024-00602-2 [Google Scholar][Crossref]
  15. Thakur S, Rana A, Sharma A, Yangchan J, Choudhary K, Kumar R, et al. Plant nematode interaction and omics: a focus on Meloidogyne incognita. J Crop Health. 2024:1-11. [Google Scholar][Crossref]
  16. Hussaini A, Isaac C, Rahimat H, Inegbenosun C, Obasuyi C, Solomon E. The burden of Bancroftian filariasis in Nigeria: a review. Ethiop J Health Sci. 2020;30(2):301-10. doi:10.4314/ejhs.v30i2.18 [Google Scholar][Crossref]
  17. Henthorn CR, Airs PM, Neumann EK, Zamanian M. Resolving the origins of secretory products and anthelmintic responses in a human parasitic nematode at single-cell resolution. Elife. 2023;12:e83100. doi:10.7554/eLife.83100 [Google Scholar][Crossref]
  18. Rajamanickam A, Babu S. Unraveling the dynamics of human filarial infections: immunological responses, host manifestations, and pathogen biology. Pathogens. 2025;14(3):223. doi:10.3390/pathogens14030223 [Google Scholar][Crossref]
  19. Bhuvaneswari A, Shriram AN, Raju KHK, Kumar A. Mosquitoes, lymphatic filariasis, and public health: a systematic review of Anopheles and Aedes surveillance strategies. Pathogens. 2023;12(12):1406. doi:10.3390/pathogens12121406 [Google Scholar][Crossref]
  20. Pouw RB, Ricklin D. Tipping the balance: intricate roles of the complement system in disease and therapy. Semin Immunopathol. 2021;43(6):757 -71. doi:10.1007/s00281-021-00892-7 [Google Scholar][Crossref]
  21. Ghafari M, Hall M, Golubchik T, Ayoubkhani D, House T, MacIntyre-Cockett G, et al. Prevalence of persistent SARS-CoV-2 in a large community surveillance study. Nature. 2024;626(8001):1094-101. [Google Scholar][Crossref]
  22. Amaechi EC, Ariyo AA, Aderogba AA, Nwachukwu PC, Nwadike CC, Ezekiel OO, et al. Burden, knowledge and perception of lymphatic filariasis in resource-poor communities in north central Nigeria. J Parasit Dis. 2024:1-8. [Google Scholar][Crossref]
  23. Siggins MK, Sriskandan S. Bacterial lymphatic metastasis in infection and immunity. Cells. 2021;11(1):33. doi:10.3390/cells11010033 [Google Scholar][Crossref]
  24. Intarapuk A, Bhumiratana A. Investigation of Armigeres subalbatus, a vector of zoonotic Brugia pahangi filariasis in plantation areas in Suratthani, Southern Thailand. One Health. 2021;13:100261. doi:10.1016/j.onehlt.2021.100261 [Google Scholar][Crossref]
  25. Bennuru S, Nutman TB. Lymphangiogenesis and lymphatic remodeling induced by filarial parasites: implications for pathogenesis. PLoS Pathog. 2009;5(12):e1000688. doi:10.1371/journal.ppat.1000688 [Google Scholar][Crossref]
  26. Jeza VT, Mutuku F, Kaduka L, Mwandawiro C, Masaku J, Okoyo C, et al. Schistosomiasis, soil transmitted helminthiasis, and malaria co-infections among women of reproductive age in rural communities of Kwale County, coastal Kenya. BMC Public Health. 2022;22(1):136. [Google Scholar][Crossref]
  27. Prichard RK. Macrocyclic lactone resistance in Dirofilaria immitis: risks for prevention of heartworm disease. Int J Parasitol. 2021;51(13-14):1121-32. doi:10.1016/j.ijpara.2021.08.006 [Google Scholar][Crossref]
  28. Wilairatana P, Kotepui KU, Mala W, Wangdi K, Kotepui M. Prevalence, probability, and characteristics of malaria and filariasis co-infections: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2022;16(10):e0010857. [Google Scholar][Crossref]
  29. Dedkhad W, Christensen BM, Bartholomay LC, Joshi D, Hempolchom C, Saeung A. Immune responses of Aedes togoi, Anopheles paraliae and Anopheles lesteri against nocturnally subperiodic Brugia malayi microfilariae International Journal of Medical and All Body Health Research www.allmedicaljournal.com during migration from the midgut to the site of development. Parasit Vectors. 2018;11(1):528. doi:10.1186/s13071-018-3120-1 [Google Scholar][Crossref]
  30. Mondal R, Azmi SA, Sinha S, Bose C, Ghosh T, Bhattacharya S, et al. Ecology and behavior. In: Mosquitoes of India: Biology, Phylotaxonomy, Host-Parasite Interaction and Resistance Development. 2025. p. 239. [Google Scholar][Crossref]
  31. Tripathi PK, Mahajan RC, Malla N, Pathak V, Gupta S, Sharma M, et al. Stage-specific antibody response against two larval stages of Brugia malayi in different clinical spectra of brugian filariasis. Trop Parasitol. 2017;7(1):29-36. doi:10.4103/2229-5070.202298 [Google Scholar][Crossref]
  32. Paludan SR, Pradeu T, Masters SL, Mogensen TH. Constitutive immune mechanisms: mediators of host defence and immune regulation. Nat Rev Immunol. 2021;21(3):137-50. [Google Scholar][Crossref]
  33. Drayton M, Deisinger JP, Ludwig KC, Raheem N, Müller A, Schneider T, et al. Host defense peptides: dual antimicrobial and immunomodulatory action. Int J Mol Sci. 2021;22(20):11172. [Google Scholar][Crossref]
  34. Ranjha R, Singh K, Baharia RK, Mohan M, Anvikar AR, Bharti PK. Age-specific malaria vulnerability and transmission reservoir among children. Glob Pediatr. 2023;6:100085. [Google Scholar][Crossref]
  35. de Jesus Ramires M, Hummel K, Hatfaludi T, Hess M, Bilic I. Host-specific targets of Histomonas meleagridis antigens revealed by immunoprecipitation. Sci Rep. 2025;15(1):5800. [Google Scholar][Crossref]
  36. Sinha A, Kumar S, Dayal D, Yadav V, Pramanik A, Chaubey KK, et al. Elimination of lymphatic filariasis: where do we stand so far? Asian Pac J Trop Med. 2023;16(9):385-99. [Google Scholar][Crossref]
  37. Novianti KK, Wahab S, Djawad K, Wospodo N, Mulawardi. Lymphedema resulting from filariasis successfully treated by surgery. J Public Health Afr. 2020;11(1):1059. doi:10.4081/jphia.2020.1059 [Google Scholar][Crossref]
  38. Wu Y, Kang L, Guo Z, Liu J, Liu M, Liang W. Incubation period of COVID-19 caused by unique SARS-CoV-2 strains: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(8):e2228008. doi:10.1001/jamanetworkopen.2022.28008 [Google Scholar][Crossref]
  39. Hattori Y, Hayashi K, Sakamoto S, Doi K. Upper extremity volume/total body volume ratio for evaluation of upper extremity lymphedema. Ann Plast Surg. 2021;86(1):35-8. [Google Scholar][Crossref]
  40. Ahmed MB, Almohannadi FS, Shraim BA, Aljassem G, Al-Lahham S, Alsherawi A, et al. Surgical written consent in aesthetic plastic surgery: a plastic center audit of surgical consent standards. Cureus. 2024;16(1):e52439. [Google Scholar][Crossref]
  41. Lenz B, Ehrens A, Ajendra J, Risch F, Gal J, Neumann AL, et al. Repeated sensitization of mice with microfilariae of Litomosoides sigmodontis induces pulmonary eosinophilia in an IL-33-dependent manner. PLoS Pathog. 2024;20(3):e0012071. [Google Scholar][Crossref]
  42. Huang L, Appleton JA. Eosinophils in helminth infection: defenders and dupes. Trends Parasitol. 2016;32(10):798-807. doi:10.1016/j.pt.2016.05.004 [Google Scholar][Crossref]
  43. D’Evelyn SM, Jung J, Alvarado E, Baumgartner J, Caligiuri P, Hagmann RK, et al. Wildfire, smoke exposure, human health, and environmental justice need to be integrated into forest restoration and management. Curr Environ Health Rep. 2022;9(3):366-85. [Google Scholar][Crossref]
  44. Setegn A, Amare GA, Mihret Y. Wolbachia and lymphatic filarial nematodes and their implications in the pathogenesis of the disease. J Parasitol Res. 2024;2024:3476951. [Google Scholar][Crossref]
  45. Abraham PR, Ramalingam B, Mohapatra P, Krishnamoorthy K, Hoti SL, Kumar A. Detection of Wuchereria bancrofti infection in mosquitoes in areas co-endemic with Brugia malayi in Balasore district, Odisha, India. Sci Rep. 2024;14(1):16780. [Google Scholar][Crossref]
  46. Mackenzie CD, Kapa DR, Krishnasastry S, Douglass J, Hoerauf A, Ottesen EA. Managing lymphedema induced by lymphatic filariasis: Implementing and improving care at the individual and programmatic levels. Am J Trop Med Hyg. 2024;111(4 Suppl):3. [Google Scholar][Crossref]
  47. Jaszkul KM, Farrokhi K, Castanov V, Minkhorst K, Li EA, Sano L, et al. Global impact of lymphedema on quality of life and society. Eur J Plast Surg. 2023;46(6):901-13. [Google Scholar][Crossref]
  48. Nadasy GL, Patai BB, Molnar AA, Hetthessy JR, Tokes AM, Varady Z, et al. Vicious circle with venous hypertension, irregular flow, pathological venous wall remodeling, and valve destruction in chronic venous disease: a review. Angiology. 2024:00033197241256680. [Google Scholar][Crossref]
  49. Kurniawan Y, Imran Y, Rahmansyah M, Rachmiyani I, Khusfiani T, Yousif E. Megadose methylprednisolone in acute traumatic spinal cord injury. Int J Neurol Sci. 2024;13:236276. [Google Scholar][Crossref]
  50. Azzahra MK, Alishya D, Shafwah CS, Adriyani R. A review of bed nets usage and sewerage conditions as risk factors for lymphatic filariasis in developing countries. J Environ Health. 2024;16(1):89-100. [Google Scholar][Crossref]
  51. Hantusch B. Morphological and functional characteristics of blood and lymphatic vessels. In: Fundamentals of Vascular Biology. Cham: Springer; 2024. p. 1-50. [Google Scholar][Crossref]
  52. Karunarathna I, Hapuarachchi T, Gunasena P, Gunathilake S. Comprehensive review of amoxicillin: indications, mechanism of action, and clinical application. ResearchGate. 2024. Available from: https://www.researchgate.net/publication/383231049 [Google Scholar][Crossref]
  53. Senoo-Dogbey VE, Ohene LA, Wuaku DA. Occupational exposure to Hepatitis B virus, disease burden and pathways for postexposure prophylaxis management: recommendations for healthcare workers in highly endemic settings. Infect Prev Pract. 2024;6(2):100354. doi:10.1016/j.infpip.2024.100354 [Google Scholar][Crossref]
  54. Goyal G, Tazi A, Go RS, Rech KL, Picarsic JL, Vassallo R, et al. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022;139(17):2601-21. [Google Scholar][Crossref]
  55. Yan W, Ma C, Cai X, Sun Y, Zhang G, Song W. Self-powered and wireless physiological monitoring system with integrated power supply and sensors. Nano Energy. 2023;108:108203. doi:10.1016/j.nanoen.2023.108203 [Google Scholar][Crossref]
  56. Mitra SK, Mishra RK, Verma P. Cytological diagnosis of microfilariae in filariasis endemic areas of eastern Uttar Pradesh. J Cytol. 2009;26(1):11 -4. doi:10.4103/0970-9371.51333 [Google Scholar][Crossref]
  57. Hertz MI, Nana-Djeunga H, Kamgno J, Jelil Njouendou A, Chawa Chunda V, Wanji S, et al. Identification and characterization of Loa loa antigens responsible for cross-reactivity with rapid diagnostic tests for lymphatic International Journal of Medical and All Body Health Research www.allmedicaljournal.com filariasis. PLoS Negl Trop Dis. 2018;12(11):e0006963. doi:10.1371/journal.pntd.0006963 [Google Scholar][Crossref]
  58. Mischlinger J, Manego RZ, Mombo-Ngoma G, Ekoka Mbassi D, Hackbarth N, Ekoka Mbassi FA, et al. Diagnostic performance of capillary and venous blood samples in the detection of Loa loa and Mansonella perstans microfilaraemia using light microscopy. PLoS Negl Trop Dis. 2021;15(8):e0009623. [Google Scholar][Crossref]
  59. KTN, Prasad K, Singh BMK. Analysis of red blood cells from peripheral blood smear images for anemia detection: A methodological review. Med Biol Eng Comput. 2022;60(9):2445-62. doi:10.1007/s11517-022-02614-z [Google Scholar][Crossref]
  60. Maldjian C, Khanna V, Tandon B, Sandhu J, Klein MJ, Gilet AG. Lymphatic filariasis disseminating to the upper extremity. Case Rep Radiol. 2014;2014:985680. doi:10.1155/2014/985680 [Google Scholar][Crossref]
  61. Greene SE, Fischer K, Choi YJ, Curtis KC, Budge PJ, Mitreva M, et al. Characterization of a novel microfilarial antigen for diagnosis of Wuchereria bancrofti infections. PLoS Negl Trop Dis. 2022;16(5):e0010407. [Google Scholar][Crossref]
  62. Weber E, Agliano M, Bertelli E, Gabriele G, Gennaro P, Barone V. Lymphatic collecting vessels in health and disease: a review of histopathological modifications in lymphedema. Lymphat Res Biol. 2022;20(5):468-77. [Google Scholar][Crossref]
  63. Hanser A, Hofbeck M, Hofmeister M, Martirosian P, Hornung A, Esser M, et al. Feasibility, classification and potential clinical impact of non-invasive delineation of abdominal lymphatic vessels in patients following TCPC with T2 weighted MRI. Sci Rep. 2024;14(1):29752. [Google Scholar][Crossref]
  64. Li H, Staxäng K, Ladak HM, Agrawal S, Rask-Andersen H. Middle ear biofilm and sudden deafness-a light and transmission electron microscopy study. Front Neurol. 2024;15:1495893. [Google Scholar][Crossref]
  65. Freitas LT, Khan MA, Uddin A, Halder JB, Singh-Phulgenda S, Raja JD, et al. The lymphatic filariasis treatment study landscape: A systematic review of study characteristics and the case for an individual participant data platform. PLoS Negl Trop Dis. 2024;18(1):e0011882. [Google Scholar][Crossref]
  66. Deribe K, Bakajika DK, Zoure HMG, Gyapong JO, Molyneux DH, Rebollo MP. African regional progress and status of the programme to eliminate lymphatic filariasis: 2000–2020. Int Health. 2021;13(Suppl 1):S22-7. [Google Scholar][Crossref]
  67. Mishra P, Vij D, Singh A, Prabhakar AE, Shrivastava A, Verma AK. An insight review on anti-filarial herbal drugs. Biochem Cell Arch. 2024;24(2). [Google Scholar][Crossref]
  68. Weil GJ, Jacobson JA, King JD. A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: from conception to delivery. Int Health. 2020;13(Suppl 1):S60-4. doi:10.1093/inthealth/ihaa046 [Google Scholar][Crossref]
  69. Malagón T, Franco EL, Tejada R, Vaccarella S. Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination. Nat Rev Clin Oncol. 2024;21(7):522-38. [Google Scholar][Crossref]
  70. Tobon Ramos JA, Maure T, Carias L, Lew D, Goss C, Samuel A, et al. Impact of mass drug administration with ivermectin, diethylcarbamazine, and albendazole for lymphatic filariasis on hookworm and Strongyloides stercoralis infections in Papua New Guinea. PLoS Negl Trop Dis. 2025;19(3):e0012851. [Google Scholar][Crossref]
  71. Ofire MO, Omanje V, Sempele I, Chami I, Gitahi PN, Njenga SM, et al. Lymphatic filariasis elimination in Kenya: tracing the journey from 2002-2024 and pathways to achieving 2030 target. Int J Infect Dis. 2025;107839. [Google Scholar][Crossref]
  72. Hatami H, Mojahedian MM, Kesharwani P, Sahebkar A. Advancing personalized medicine with 3D printed combination drug therapies: a comprehensive review of application in various conditions. Eur Polym J. 2024;113245. [Google Scholar][Crossref]
  73. Farid Y, Pozzi M, Bolletta A, Cigna E, Losco L, Mendes VM, et al. Effective management strategies for primary lymphedema of the lower extremities: integrating conservative and surgical therapies in early and late stages. Microsurgery. 2025;45(1):e70014. [Google Scholar][Crossref]
  74. Tran HM, MacQueen I, Chen D, Simons M. Systematic review and guidelines for management of scrotal inguinal hernias. J Abdom Wall Surg. 2023;2:11195. [Google Scholar][Crossref]
  75. Loh HH, Shahar MA, Loh HS, Yee A. Female sexual dysfunction after bariatric surgery in women with obesity: a systematic review and meta-analysis. Scand J Surg. 2022;111(1):14574969211072395. [Google Scholar][Crossref]
  76. Xu N, Cai Y, Tong Y, Tang L, Zhou Y, Gong Y, et al. Prediction on the spatial distribution of the seropositive rate of schistosomiasis in Hunan Province, China: A machine learning model integrated with the Kriging method. Parasitol Res. 2024;123(9):316. [Google Scholar][Crossref]
  77. Brown S, Dayan JH, Kataru RP, Mehrara BJ. The vicious circle of stasis, inflammation, and fibrosis in lymphedema. Plast Reconstr Surg. 2023;151(2):330e-41e. [Google Scholar][Crossref]
  78. Cozer AWD, Souza FCV, Santiago LD, Lima MR, Pimenta SJ, Fernandes BL, et al. Effects of iron-fortified foods on the nutritional status of children residing in regions vulnerable to parasitic diseases: A systematic review. Prev Nutr Food Sci. 2024;29(1):8-17. doi:10.3746/pnf.2024.29.1.8 [Google Scholar][Crossref]
  79. Nyirenda C, Gondwe K, Maksoud G, Chimese M, Maliko C. Contrasting lymphatic filariasis with Kaposi sarcoma in a known HIV disease patient: a clinical and histopathological presentation and implication to care. Clin Med Health Res J. 2022;2(6):255-7. [Google Scholar][Crossref]
  80. Pantelias A, King JD, Lammie P, Weil GJ. Development and introduction of the filariasis test strip: A new diagnostic test for the global program to eliminate lymphatic filariasis. Am J Trop Med Hyg. 2022;106(5 Suppl):56. [Google Scholar][Crossref]
  81. Abajue MC, Wogu MN. Medicinal plants in the tropics used in the treatment and management of parasitic diseases transmitted by mosquitoes: administration, challenges, and strategic options for management. In: Herbal Medicine Phytochemistry: Applications and Trends. Cham: Springer; 2023. p. 1-34. [Google Scholar][Crossref]
  82. Talaga S, Le Goff G, Arana-Guardia R, Baak-Baak CM, García-Rejón JE, García-Suárez O, et al. The mosquitoes (Diptera: Culicidae) of the Mexican Yucatan Peninsula: a comprehensive review on the use of taxonomic names. J Med Entomol. 2024;61(2):274-308. [Google Scholar][Crossref]
  83. Kimura E. The global programme to eliminate lymphatic filariasis: History and achievements with special reference to annual single-dose treatment with diethylcarbamazine in Samoa and Fiji. Trop Med Health. 2011;39(1):17-30. doi:10.2149/tmh.2010-18 [Google Scholar][Crossref]
  84. Weil GJ, Jacobson JA, King JD. A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: International Journal of Medical and All Body Health Research www.allmedicaljournal.com from conception to delivery [published correction appears in Int Health. 2021;13(5):492]. Int Health. 2020;13(Suppl 1):S60-4. [Google Scholar][Crossref]
  85. Bartilol B, Babu L, Garama K, Karisa J, Kamau A, Mwandawiro C, et al. Molecular xenomonitoring reveals Anopheles funestus and An. rivulorum as the primary vectors of lymphatic filariasis in coastal Kenya. Parasit Vectors. 2024;17(1):425. [Google Scholar][Crossref]
  86. Lupenza ET, Gasarasi DB, Minzi OM. Lymphatic filariasis elimination status: Wuchereria bancrofti infections in human populations and factors contributing to continued transmission after seven rounds of mass drug administration in Masasi District, Tanzania. PLoS One. 2022;17(1):e0012693. doi:10.1371/journal.pone.0262693 [Google Scholar][Crossref]
  87. Jones C, Ngasalla B, Derua YA, Tarimo D, Malecela MN. Lymphatic filariasis elimination efforts in Rufiji, southeastern Tanzania: decline in circulating filarial antigen prevalence in young school children after twelve rounds of mass drug administration and utilization of long-lasting insecticide-treated nets. Int J Infect Dis. 2017;61:38-43. doi:10.1016/j.ijid.2017.05.009 [Google Scholar][Crossref]
  88. Brady MA, Toubali E, Baker M, Long E, Worrell C, Ramaiah K, et al. Persons ‘never treated’ in mass drug administration for lymphatic filariasis: Identifying programmatic and research needs from a series of research review meetings 2020–2021. Int Health. 2024;16(5):479-86. [Google Scholar][Crossref]
  89. Turner HC. Health economic analyses of the global programme to eliminate lymphatic filariasis. Int Health. 2020;13(Suppl 1):S71-4. doi:10.1093/inthealth/ihaa095 [Google Scholar][Crossref]
  90. Mollick ER, Mollick L. Using AI to implement effective teaching strategies in classrooms: five strategies, including prompts. SSRN. 2023. Available from: https://ssrn.com/abstract=4391243 [Google Scholar][Crossref]
  91. Perera M, Whitehead M, Molyneux D, Weerasooriya M, Gunatilleke G. Neglected patients with a neglected disease? A qualitative study of lymphatic filariasis. PLoS Negl Trop Dis. 2007;1(2):e128. doi:10.1371/journal.pntd.0000128 [Google Scholar][Crossref]
  92. Winfield AS, Hickerson H, Doub DC, Winfield AR, McPhatter B. Between Black mothers and daughters: a critical intergenerational duoethnography on the silence of health disparities and hope of loud healing. Front Commun. 2024;8:1185919. [Google Scholar][Crossref]
  93. Hossain MS, Hatta T, Labony SS, Kwofie KD, Kawada H, Tsuji N, et al. Food-and vector-borne parasitic zoonoses: global burden and impacts. Adv Parasitol. 2023;120:87-136. [Google Scholar][Crossref]
  94. Nnaji ND, Onyeaka H, Reuben RC, Uwishema O, Olovo CV, Anyogu A. The deuce-ace of Lassa Fever, Ebola virus disease and COVID-19 simultaneous infections and epidemics in West Africa: clinical and public health implications. Trop Med Health. 2021;49(1):102. [Google Scholar][Crossref]
  95. Mackenzie CD, Mante S. Caring for patients in the global programme to eliminate lymphatic filariasis. Int Health. 2020;13(Suppl 1):S48 -54. doi:10.1093/inthealth/ihaa080 [Google Scholar][Crossref]
  96. Mathew CG, Bettis AA, Chu BK, English M, Ottesen EA, Bradley MH, et al. The health and economic burdens of lymphatic filariasis prior to mass drug administration programs. Clin Infect Dis. 2020;70(12):2561-7. doi:10.1093/cid/ciz671 [Google Scholar][Crossref]
  97. Khaemba C, Njenga SM, Omondi WP, Kirui E, Oluka M, Guantai A, et al. Safety and effectiveness of triple-drug therapy with ivermectin, diethylcarbamazine, and albendazole in reducing lymphatic filariasis prevalence and clearing circulating filarial antigens in Mombasa, Kenya. Infect Dis Poverty. 2025;14(1):11. [Google Scholar][Crossref]
  98. Sayyaf Dezfuli B, Lorenzoni M, Carosi A, Giari L, Bosi G. Teleost innate immunity, an intricate game between immune cells and parasites of fish organs: who wins, who loses. Front Immunol. 2023;14:1250835. [Google Scholar][Crossref]
  99. Hegde S, Marriott AE, Pionnier N, Steven A, Bulman C, Gunderson E, et al. Combinations of the azaquinazoline anti-Wolbachia agent, AWZ1066S, with benzimidazole anthelmintics synergise to mediate sub-seven-day sterilising and curative efficacies in experimental models of filariasis. Front Microbiol. 2024;15:1346068. [Google Scholar][Crossref]
  100. Antonucci L, Seo H, Strobl M. Quantity over quality? How economic factors and welfare state interventions affected job insecurity and job quality before, during and after the economic crises. Soc Policy Adm. 2024;58(2):277-98. doi:10.1111/spol.13003 [Google Scholar][Crossref]
  101. Njenga SM, Kanyi H, Okoyo C, Githinji E, Mwatele C, Matendechero SH, et al. Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: programmatic implementation and results of the first impact assessment. PLoS Negl Trop Dis. 2024;18(7):e0011942. [Google Scholar][Crossref]
  102. Chavda VP, Pandya A, Pulakkat S, Soniwala M, Patravale V. Lymphatic filariasis vaccine development: neglected for how long? Expert Rev Vaccines. 2021;20(11):1471-82. [Google Scholar][Crossref]
  103. Shey RA, Ghogomu SM, Shintouo CM, Nkemngo FN, Nebangwa DN, Esoh K, et al. Computational design and preliminary serological analysis of a novel multi-epitope vaccine candidate against onchocerciasis and related filarial diseases. Pathogens. 2021;10(2):99. [Google Scholar][Crossref]
  104. Aarthy M, Pandiyan GN, Paramasivan R, Kumar A, Gupta B. Identification and prioritisation of potential vaccine candidates using subtractive proteomics and designing of a multi-epitope vaccine against Wuchereria bancrofti. Sci Rep. 2024;14(1):1970. doi:10.1038/s41598-024-52457-x [Google Scholar][Crossref]
  105. Zhu G, Tong N, Zhu Y, Wang L, Wang Q. The crosstalk between SUMOylation and immune system in host-pathogen interactions. Crit Rev Microbiol. 2025;51(1):164-86. [Google Scholar][Crossref]
  106. Lim HX, Lim J, Poh CL. Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine. Med Microbiol Immunol. 2021;210(1):1-11. doi:10.1007/s00430-021-00700-x [Google Scholar][Crossref]
  107. Coombes L, Bristowe K, Ellis-Smith C, Aworinde J, Fraser LK, Downing J, et al. Enhancing validity, reliability and participation in self-reported health outcome measurement for children and young people: a systematic review of recall period, response scale format, and administration modality. Qual Life Res. 2021;30:1803-32. [Google Scholar][Crossref]
  108. Chimfwembe K, Shirley H, Baker N, Wamai R. Zambia: a narrative review of success and challenges in lymphatic filariasis elimination. Trop Med Infect Dis. 2024;9(1):21. doi:10.3390/tropicalmed9010021 [Google Scholar][Crossref]
  109. Kapa DR, Mohamed AJ. Progress and impact of 20 years of a lymphatic filariasis elimination programme in South-East Asia. Int Health. 2020;13(Suppl 1):S17-21. International Journal of Medical and All Body Health Research www.allmedicaljournal.com doi:10.1093/inthealth/ihaa056 [Google Scholar][Crossref]
  110. Ottesen EA, Horton J. Setting the stage for a global programme to eliminate lymphatic filariasis: the first 125 years (1875-2000). Int Health. 2020;13(Suppl 1):S3-9. doi:10.1093/inthealth/ihaa061 [Google Scholar][Crossref]
  111. Smith ME, Newcomb K, Otano YA, Michael E. A hierarchical model-based framework for evaluating probabilities of area-wide freedom from lymphatic filariasis infection based on sentinel site surveillance data. Front Trop Dis. 2023;4:1233763. [Google Scholar][Crossref]
  112. Ramaiah KD, Ottesen EA. Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS Negl Trop Dis. 2014;8(11):e3319. doi:10.1371/journal.pntd.0003319 [Google Scholar][Crossref]
  113. Krentel A, Gyapong M, McFarland DA, Ogundahunsi O, Titaley CR, Addiss DG. Keeping communities at the centre of efforts to eliminate lymphatic filariasis: learning from the past to reach a future free of lymphatic filariasis. Int Health. 2021;13(Suppl 1):S55-9. [Google Scholar][Crossref]
  114. du Preez K, Gabardo BMA, Kabra SK, Triasih R, Lestari T, Kal M, et al. Priority activities in child and adolescent tuberculosis to close the policy-practice gap in low-and middle-income countries. Pathogens. 2022;11(2):196. [Google Scholar][Crossref]
  115. Nunes C, McKee M, Howard N. The role of global health partnerships in vaccine equity: a scoping review. PLOS Glob Public Health. 2024;4(2):e0002834. doi:10.1371/journal.pgph.0002834 [Google Scholar][Crossref]
  116. Santoro M, Shanklin R. Human rights obligations of drug companies. In: Rights at Stake and the COVID-19 Pandemic. Routledge; 2023. p. 43-53. [Google Scholar][Crossref]
  117. Storeng KT, de Bengy Puyvallée A, Stein F. COVAX and the rise of the 'super public private partnership' for global health. Glob Public Health. 2023;18(1):1987502. doi:10.1080/17441692.2021.1987502 [Google Scholar][Crossref]
  118. Srividya A, Subramanian S, Jambulingam P, Vijayakumar B, Dinesh Raja J. Mapping and monitoring for a lymphatic filariasis elimination program: a systematic review. Res Rep Trop Med. 2019;10:43-90. doi:10.2147/RRTM.S134186 [Google Scholar][Crossref]
  119. Mboi N, Syailendrawati R, Ostroff SM, Elyazar IR, Glenn SD, Rachmawati T, et al. The state of health in Indonesia’s provinces, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Glob Health. 2022;10(11):e1632-45. [Google Scholar][Crossref]
  120. Xu H, Cao Y, Yu D, Cao M, He Y, Gill M, et al. Ensuring effective implementation of the post-2020 global biodiversity targets. Nat Ecol Evol. 2021;5(4):411-8. [Google Scholar][Crossref]
  121. Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low‐ and middle‐income countries: a review with particular focus on Africa. Br J Clin Pharmacol. 2023;89(2):491-509. [Google Scholar][Crossref]
  122. Jacobsen KH, Andress BC, Bhagwat EA, Bryant CA, Chandrapu VR, Desmonts CG, et al. A call for loiasis to be added to the WHO list of neglected tropical diseases. Lancet Infect Dis. 2022;22(10):e299-302. [Google Scholar][Crossref]
  123. Sartorius B, Cano J, Simpson H, Tusting LS, Marczak LB, Miller-Petrie MK, et al. Prevalence and intensity of soil-transmitted helminth infections of children in sub-Saharan Africa, 2000–18: a geospatial analysis. Lancet Glob Health. 2021;9(1):e52-60. [Google Scholar][Crossref]
  124. De Souza DK, Otchere J, Ahorlu CS, Adu-Amankwah S, Larbi IA, Dumashie E, et al. Low microfilaremia levels in three districts in coastal Ghana with at least 16 years of mass drug administration and persistent transmission of lymphatic filariasis. Trop Med Infect Dis. 2018;3(4):105. doi:10.3390/tropicalmed3040105 [Google Scholar][Crossref]
  125. Bienvenu Nwane P, Djeunga HCN, Toche NN, Domché A, Bertrand FN, Niamsi YE, et al. Status of human onchocerciasis transmission in the Adamaoua region of Cameroon after 20 years of ivermectin mass distribution. PLoS Negl Trop Dis. 2025;19(3):e0011511. [Google Scholar][Crossref]
  126. Subbarao S, Thompson R, Klion A, Hauck FR, Thomas TA. Cases of loiasis among a Congolese family: screening for loiasis among newly arrived refugees from endemic areas. J Nurse Pract. 2023;19(3):104505. [Google Scholar][Crossref]
  127. Bowden SJ, Doulgeraki T, Bouras E, Markozannes G, Athanasiou A, Grout-Smith H, et al. Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and follow-up Mendelian randomisation studies. BMC Med. 2023;21(1):274. [Google Scholar][Crossref]
  128. Odejimi A, Quinley J, Eluwa GI, Kunnuji M, Wammanda RD, Weiss W, et al. Causes of deaths in neonates and children aged 1–59 months in Nigeria: verbal autopsy findings of 2019 Verbal and Social Autopsy study. BMC Public Health. 2022;22(1):1130. [Google Scholar][Crossref]
  129. Santin M, Ng-Hublin JS, Maloney JG. Detection of gastrointestinal protists. In: Recent Advancements in the Diagnosis of Human Disease. 2024. p. 46-103. [Google Scholar][Crossref]
  130. Li F, Lu H, Hou M, Cui K, Darbandi M. Customer satisfaction with bank services: the role of cloud services, security, e-learning and service quality. Technol Soc. 2021;64:101694. [Google Scholar][Crossref]
  131. De Prins L, Raap U, Mueller T, Schmid-Grendelmeier P, Haase CH, Backer V, et al. White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA. Front Allergy. 2022;3:889221. [Google Scholar][Crossref]
  132. Kulkarni SS, Bland S, Gaeta JM. From support to action: a critical affinity group of special education teachers of color. Teach Educ Spec Educ. 2022;45(1):43-60. [Google Scholar][Crossref]
  133. Addiss DG, Brady MA. Morbidity management in the global programme to eliminate lymphatic filariasis: a review of the scientific literature. Filaria J. 2007;6:2. doi:10.1186/1475-2883-6-2 [Google Scholar][Crossref]
  134. Binkienė R, Vanstreels RET, Duc M, Bernotienė R. Description and circadian rhythms of Chandlerella sinensis Li, 1933 (Nematoda; Onchocercidae), with remarks of microfilariae effects on the host health. Parasitology. 2024;151(7):732 -43. doi:10.1017/S0031182024000738 [Google Scholar][Crossref]
  135. Mehta PK, Maharjan M. Assessment of antigenemia among children in four hotspots of filarial endemic districts of Nepal during post-MDA surveillance. Trop Med Health. 2023;51:47. doi:10.1186/s41182-023-00538-4 [Google Scholar][Crossref]
  136. Krishnasastry S, Ashok A, Devidas A, Sullivan S, Stephens M, Norman J, et al. Efficacy and safety of adding 6 weeks of doxycycline to the essential package of care to treat filarial lymphedema: A double-blind, randomized, controlled trial in Southern India. Am J Trop Med Hyg. 2024;111(4 Suppl):83. [Google Scholar][Crossref]
  137. Geary TG, Long A, Tritten L. Current antifilarial drugs– mechanisms of action. In: Human and Animal Filariases: Landscape, Challenges, and Control. 2022. p. 249-81. [Google Scholar][Crossref]
  138. Elouardi C, Lefort A, Deconinck L, Peiffer-Smadja N, International Journal of Medical and All Body Health Research www.allmedicaljournal.com Houzé S, Argy N. Imported loiasis: Diagnostic and therapeutic challenges. Infect Dis Now. 2025;105053. [Google Scholar][Crossref]
  139. Yadav A, Yadav S, Alam A. A landscape on lymphatic filariasis with its effects and recent advanced treatments. Recent Adv Anti-Infect Drug Discov. 2024;19(3):197-215. [Google Scholar][Crossref]
  140. Won KY, Gass K, Biamonte M, Dagne DA, Ducker C, Hanna C, et al. Diagnostics to support elimination of lymphatic filariasis—development of two target product profiles. PLoS Negl Trop Dis. 2021;15(11):e0009968. [Google Scholar][Crossref]
  141. Jordan KC, Di Gennaro JL, von Saint André-von Arnim A, Stewart BT. Global trends in pediatric burn injuries and care capacity from the World Health Organization Global Burn Registry. Front Pediatr. 2022;10:954995. [Google Scholar][Crossref]
  142. Simpson H, Konan DO, Brahima K, Koffi JDA, Kashindi S, Edmiston M, et al. Effectiveness of community-based burden estimation to achieve elimination of lymphatic filariasis: A comparative cross-sectional investigation in Côte d’Ivoire. PLoS Glob Public Health. 2022;2(8):e0000760. [Google Scholar][Crossref]
  143. Lawford H, Mayfield H, Sam FA, Aye KS, Htwe KM, Roineau M, et al. Anti-filarial antibodies are sensitive indicators of lymphatic filariasis transmission and enable identification of high-risk populations and hotspots. Int J Infect Dis. 2024;147:107194. doi:10.1016/j.ijid.2024.107194 [Google Scholar][Crossref]
  144. Dickson BF, Masson JJ, Mayfield HJ, Aye KS, Htwe KM, Roineau M, et al. Bayesian network analysis of lymphatic filariasis serology from Myanmar shows benefit of adding antibody testing to post-MDA surveillance. Trop Med Infect Dis. 2022;7(7):113 [Google Scholar][Crossref]

How to Cite

Kamal, I. K., Mahmood, A. T., & Al-Hamadany, A. Y. (2025). All What You Need To Know About the Lymphatic Filariasis. International Journal of Medical and All Body Health Research, 6(3), 42-61. https://doi.org/10.54660/IJMBHR.2025.6.3.42-61

Kamal, Islam Khalid, et al. "All What You Need To Know About the Lymphatic Filariasis." International Journal of Medical and All Body Health Research, vol. 6, no. 3, 2025, pp. 42-61. https://doi.org/10.54660/IJMBHR.2025.6.3.42-61.

Kamal, I. K., Mahmood, A. T. and Al-Hamadany, A. Y. (2025) 'All What You Need To Know About the Lymphatic Filariasis', International Journal of Medical and All Body Health Research, 6(3), pp. 42-61. doi: 10.54660/IJMBHR.2025.6.3.42-61.

Kamal IK, Mahmood AT, Al-Hamadany AY. All What You Need To Know About the Lymphatic Filariasis. International Journal of Medical and All Body Health Research. 2025;6(3):42-61. doi:10.54660/IJMBHR.2025.6.3.42-61

Similar Articles

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex Scilit Crossref ResearchGate BASE

A newly published article may take a few days to appear on these services.